链激酶治疗老年急性心肌梗死的临床分析

目的　探讨链激酶 (SK )治疗老年急性心肌梗死 (AMI)患者的疗效。方法　对 138例链激酶静脉溶栓治疗的患者进行临床分析 ,按年龄分组 ,对溶栓后冠状动脉再通率、心脏事件发生率、病死率及出血并发症作临床分析。结果　 >6 5岁组的患者其血管再通率、心脏事件发生率、病死率及出血并发症与≤ 6 5岁的患者比较差异无显著性 [(70 .5 %比 77.7% (P >0 .0 5 ) ;40 .9%比 40 .4% (P >0 .0 5 ) ;15 .9%比 10 .6 % (P >0 .0 5 ) ;11.4%比 10 .6 % (P >0 .0 5 ) ]。结论　链激酶静脉溶栓治疗老年急性心肌梗死患者安全可行 ,但要视每位患者具体情况而定。

Clinical study on senile acute myocardial infarction treated with streptokinase

Objective　To study the effect of intravenous streptokinase (SK) for thrombolytic therapy on senile acute myocardial infarction (AMI).Methods　138 patients with senile AMI were treated by intravenous SK. After thrombolysis, the efficacy in two groups (age>65 yrs and age≤65 yrs) were compared with each other.Results　The reperfusion rates, incidences of heart side effect, mortalities and incidences of bleeding complication between the two groups had no significant differences (P>0.05).Conclusion　It is safe to treat senile acute myocardial infarction by intravenous SK thrombolysis according conditions of individuals.